While no studies have specifically investigated the effect of these molecules on clinical endpoints in patients with CHF, in an observational study on patients with Alzheimer’s disease without a history of CHF, the use of AChE inhibitors was associated with a significantly lower risk of new-onset CHF and cardiovascular death compared to propensity-score-matched non-users [102]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.